Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine…
New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each…
BASEL, 14-Sep-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data for the phase III BRIM8 study, which…
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1…
First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy…
New results from the phase III GALLIUM study which compared Gazyva/Gazyvaro (obinutuzumab) plus chemotherapy to Rituxan/ MabThera (rituximab) plus chemotherapy…
15 oral presentations from 17 abstracts across six autoimmune conditions First presentation of Actemra/RoActemra data from GiACTA - the largest…
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib BASEL, 11-7-2014 — /EuropaWire/…